Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$78.97

0.435 (0.55%)

10:33
10/18/16
10/18
10:33
10/18/16
10:33

Eli Lilly announces $90M investment in Lilly Global Health Partnership

Eli Lilly announced a plan to increase access to quality health care and to improve long-term health for millions of people worldwide, with an aim to reach 30 million people in resource-limited settings annually by 2030. The cornerstone of this goal - known as "Lilly 30x30" - is a new five-year, $90M investment in the Lilly Global Health Partnership, which will improve access to treatment for diabetes, cancer and tuberculosis. One-half of the $90M commitment will come from the Eli Lilly and Company Foundation; the other half will come from company funds. The $90M investment will accelerate the company's and the Foundation's global health work with key international, national and local partners. The Lilly Global Health Partnership will expand current work in diabetes and TB and add cancer as a new therapeutic area of focus. To reach 30M people annually in communities with limited resources - a six-fold increase over the number reached today - Lilly will explore new approaches within different areas of its business, the company added.

  • 25

    Oct

  • 06

    Nov

LLY Eli Lilly
$78.97

0.435 (0.55%)

09/27/16
GSCO
09/27/16
UPGRADE
Target $95
GSCO
Buy
Eli Lilly upgraded to Buy from Neutral at Goldman
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
09/27/16
09/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Neutral at Goldman with analyst Jami Rubin saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. 2. AutoZone (AZO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying the company is at a positive inflection in 7 year and older vehicles, which is strongly correlated to same-store-sales. 3. Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI with analyst Greg Gordon saying the joint settlement proposal filed in the CECONY rate case mitigates downside risk. 4. Crown Holdings (CCK) upgraded on multiple catalysts at BMO Capital with analyst Mark Wilde citing valuation, his belief that the company will resume returning cash to shareholders in 2017, and his belief that the company's results should be boosted by " a wave of domestic and offshore expansion projects." 5. Francesca's (FRAN) upgraded to Buy from Hold at Stifel with analyst Richard Jaffe saying the company's "appealing merchandise" makes it very likely that its sales will grow going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.

TODAY'S FREE FLY STORIES

12:40
06/22/17
06/22
12:40
06/22/17
12:40
General news
Fed's Bullard: balance sheet unwind should start "sooner rather than later," »

Fed's Bullard:…

GE

General Electric

$27.70

-0.08 (-0.29%)

12:36
06/22/17
06/22
12:36
06/22/17
12:36
Periodicals
Nelson Peltz's Trian optimistic about GE, Flannery, CNBC reports »

Nelson Peltz's Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 02

    Oct

FB

Facebook

$153.91

1.66 (1.09%)

, SNAP

Snap

$17.73

0.46 (2.66%)

12:33
06/22/17
06/22
12:33
06/22/17
12:33
Periodicals
Instagram job listing signals pursuit of Hollywood ties, CNBC says »

Facebook's (FB)…

FB

Facebook

$153.91

1.66 (1.09%)

SNAP

Snap

$17.73

0.46 (2.66%)

GOOG

Alphabet

$959.45

8.82 (0.93%)

GOOGL

Alphabet Class A

$978.59

9.6 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

HCA

HCA Holdings

$87.21

3.16 (3.76%)

, LPNT

LifePoint

$64.85

0.25 (0.39%)

12:31
06/22/17
06/22
12:31
06/22/17
12:31
Hot Stocks
Hospitals, insurers rise after Republicans release draft of ACA replacement bill »

Shares of hospital and…

HCA

HCA Holdings

$87.21

3.16 (3.76%)

LPNT

LifePoint

$64.85

0.25 (0.39%)

THC

Tenet

$19.14

1.455 (8.23%)

CYH

Community Health

$9.60

0.775 (8.79%)

QHC

Quorum Health

$4.43

0.335 (8.19%)

AET

Aetna

$154.14

2.04 (1.34%)

ANTM

Anthem

$194.21

2.14 (1.11%)

CNC

Centene

$82.57

2.45 (3.06%)

CI

Cigna

$172.08

1.895 (1.11%)

HUM

Humana

$240.25

4.04 (1.71%)

MOH

Molina Healthcare

$71.57

1.84 (2.64%)

UNH

UnitedHealth

$187.73

2.81 (1.52%)

WCG

WellCare

$183.58

6.04 (3.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

TECK

Teck Resources

$16.13

0.825 (5.39%)

12:30
06/22/17
06/22
12:30
06/22/17
12:30
Options
Defensive option play in Teck Resources as shares rally »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.91

1.66 (1.09%)

12:22
06/22/17
06/22
12:22
06/22/17
12:22
Hot Stocks
Facebook holds communities event, announces new mission »

Facebook hosted its first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

FLR

Fluor

$44.29

0.52 (1.19%)

12:20
06/22/17
06/22
12:20
06/22/17
12:20
Options
Flour calls seeing opening interest »

Flour calls seeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
06/22/17
06/22
12:17
06/22/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
06/22/17
06/22
12:16
06/22/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$13.99

0.94 (7.20%)

12:10
06/22/17
06/22
12:10
06/22/17
12:10
Options
Notable call buying in Canadian Solar as shares shine »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:10
06/22/17
06/22
12:10
06/22/17
12:10
General news
Treasury Option Action: a call 1x2 on 10s »

Treasury Option Action: a…

SRSC

Sears Canada

$0.47

-0.115 (-19.69%)

12:05
06/22/17
06/22
12:05
06/22/17
12:05
Hot Stocks
Breaking Hot Stocks news story on Sears Canada »

Sears Canada trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$37.08

-0.15 (-0.40%)

, GOOG

Alphabet

$959.45

8.82 (0.93%)

12:01
06/22/17
06/22
12:01
06/22/17
12:01
Hot Stocks
Nielsen launches mobile measurement for YouTube ads »

Nielsen (NLSN) announced…

NLSN

Nielsen

$37.08

-0.15 (-0.40%)

GOOG

Alphabet

$959.45

8.82 (0.93%)

GOOGL

Alphabet Class A

$978.59

9.6 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AKS

AK Steel

$6.25

0.055 (0.89%)

12:00
06/22/17
06/22
12:00
06/22/17
12:00
Options
AK Steel Jul 8 calls are today's most active option »

AK Steel Jul 8 calls are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CVM

CEL-SCI

$1.75

0.0576 (3.41%)

11:58
06/22/17
06/22
11:58
06/22/17
11:58
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI 

Cel Sci trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

11:55
06/22/17
06/22
11:55
06/22/17
11:55
Hot Stocks
Hain Celestial CEO says he has a strong management team backing him »

The Hain Celestial CEO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jun

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

, AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

11:53
06/22/17
06/22
11:53
06/22/17
11:53
Hot Stocks
Hain Celestial says Amazon deal for Whole Foods will give more exposure »

The Hain Celestial CEO is…

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

WFM

Whole Foods

$43.26

0.48 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jun

  • 28

    Jun

SPLS

Staples

$8.66

-0.09 (-1.03%)

11:47
06/22/17
06/22
11:47
06/22/17
11:47
Recommendations
Staples analyst commentary  »

Staples intrinsic value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMSI

Merit Medical

$36.80

-0.2 (-0.54%)

11:46
06/22/17
06/22
11:46
06/22/17
11:46
Recommendations
Merit Medical analyst commentary  »

Merit Medical allowance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

FSLR

First Solar

$37.23

1.78 (5.02%)

11:45
06/22/17
06/22
11:45
06/22/17
11:45
Options
First Solar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

ABBV

AbbVie

$72.80

1.455 (2.04%)

11:44
06/22/17
06/22
11:44
06/22/17
11:44
Upgrade
AbbVie rating change  »

AbbVie upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$18.47

0.06 (0.33%)

11:38
06/22/17
06/22
11:38
06/22/17
11:38
Hot Stocks
Breaking Hot Stocks news story on Commercial Metals »

Commercial Metals says a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LPNT

LifePoint

$64.85

0.25 (0.39%)

, CYH

Community Health

$9.56

0.74 (8.39%)

11:35
06/22/17
06/22
11:35
06/22/17
11:35
Hot Stocks
Hosptial stocks at highs after Republicans release ACHA 'discussion draft' »

Publicly traded companies…

LPNT

LifePoint

$64.85

0.25 (0.39%)

CYH

Community Health

$9.56

0.74 (8.39%)

THC

Tenet

$18.94

1.26 (7.13%)

HCA

HCA Holdings

$87.44

3.39 (4.03%)

UHS

Universal Health

$116.28

3.06 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$38.27

0.85 (2.27%)

11:26
06/22/17
06/22
11:26
06/22/17
11:26
Periodicals
Mylan investors vote against executive pay, re-elect board members, Reuters says »

Mylan shareholders voted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 13

    Jul

  • 03

    Sep

  • 09

    Oct

11:25
06/22/17
06/22
11:25
06/22/17
11:25
General news
Treasury announced an $88 B package of coupon offerings for next week »

Treasury announced an $88…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.